Automated red blood cell exchange with a post-procedure haematocrit targeted at 34% in the chronic management of sickle cell disease.
blood transfusion
erythropoiesis
iron deficiency
iron overload
sickle cell disease
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
30 Jul 2024
30 Jul 2024
Historique:
received:
16
03
2024
accepted:
17
07
2024
medline:
31
7
2024
pubmed:
31
7
2024
entrez:
31
7
2024
Statut:
aheadofprint
Résumé
Optimal targets for red blood cell exchange (RCE) are not well defined in the chronic management of sickle cell disease. We analysed transfusion requirements and iron-related outcomes in 101 patients on chronic RCE with a post-procedure haematocrit (Ht) targeted at 34%, which is higher than typically used. A majority were of HbSS/HbSβ0 genotype (n = 72) and enrolled for neurological complications (n = 53). Fifty patients had a positive Ht balance with RCE (>2% mean increase from pre-procedure level), while 43 patients maintained a neutral balance. The first group required fewer red blood cell units/year (65 vs. 80, p < 0.001), but a significant proportion were iron overloaded based on R2* with liver MRI (32% vs. none performed) and prescription of iron chelation (52% vs. 0%, p < 0.001, after a median of 19 months). The second group was more likely to receive iron supplementation (6% vs. 56%, p < 0.001). Chronic automated RCE with a post-procedure Ht targeted at 34% is not iron-neutral, and personalized Ht goals may be more appropriate in certain settings. This higher target should be compared with a lower Ht strategy in individuals with similar baseline red cell volumes to assess iron homeostasis and blood product requirements.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Boye‐Doe A, Brown E, Puri‐Sharma C, Chawla A, Field JJ, Neumayr LD, et al. The Grndad Registry: contemporary natural history data and an analysis of real‐world patterns of use and limitations of disease modifying therapy in adults with SCD. Blood. 2020;136:34–36.
Chou ST, Alsawas M, Fasano RM, Field JJ, Hendrickson JE, Howard J, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355.
Coates TD, Wood JC. How we manage iron overload in sickle cell patients. Br J Haematol. 2017;177(5):703–716.
Uter S, An HH, Linder GE, Kadauke S, Sesok‐Pizzini D, Kim HC, et al. Measures to reduce red cell use in patients with sickle cell disease requiring red cell exchange during a blood shortage. Blood Adv. 2021;5(12):2586–2592.
Aslan E, Luo JW, Lesage A, Paquin P, Cerny M, Chin AS‐L, et al. MRI‐based R2* mapping in patients with suspected or known iron overload. Abdom Radiol. 2021;46:2505–2515.
Swerdlow PS. Red cell exchange in sickle cell disease. ASH Educ Prog Book. 2006;2006(1):48–53.
Notice d'accompagnement portant sur les produits sanguins labiles (Héma‐Québec). 2023.
Tsitsikas DA, Badle S, Hall R, Meenan J, Bello‐Sanyaolu O, Orebayo F, et al. Automated red cell exchange in the management of sickle cell disease. J Clin Med. 2021;10(4):767.
Kelly S, Quirolo K, Marsh A, Neumayr L, Garcia A, Custer B. Erythrocytapheresis for chronic transfusion therapy in sickle cell disease: survey of current practices and review of the literature. Transfusion. 2016;56(11):2877–2888.
Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Haematol. 2017;176(2):179–191.
Biller E, Zhao Y, Berg M, Boggio L, Capocelli KE, Fang DC, et al. Red blood cell exchange in patients with sickle cell disease—indications and management: a review and consensus report by the therapeutic apheresis subsection of the AABB. Transfusion. 2018;58(8):1965–1972.
Serjeant G. Blood transfusion in sickle cell disease: a cautionary tale. Lancet. 2003;361(9369):1659–1660.
Rackoff WR, Ohene‐Frempong K, Month S, Scott JP, Neahring B, Cohen AR. Neurologic events after partial exchange transfusion for priapism in sickle cell disease. J Pediatr. 1992;120(6):882–885.
Frye RE. Reversible posterior leukoencephalopathy syndrome in sickle‐cell anemia. Pediatr Neurol. 2009;40(4):298–301.
Ballas SK, Kuypers FA, Gordeuk VR, Hankins JS, Thompson AA, Vichinsky E. Time to rethink haemoglobin threshold guidelines in sickle cell disease. Br J Haematol. 2021;195(4):518–522.
Hilliard LM, Williams BF, Lounsbury AE, Howard TH. Erythrocytapheresis limits iron accumulation in chronically transfused sickle cell patients. Am J Hematol. 1998;59(1):28–35.
Cabibbo S, Fidone C, Garozzo G, Antolino A, Manenti GO, Bennardello F, et al. Chronic red blood cell exchange to prevent clinical complications in sickle cell disease. Transfus Apher Sci. 2005;32(3):315–321.
de Montalembert M, Ribeil J‐A, Brousse V, Guerci‐Bresler A, Stamatoullas A, Vannier J‐P, et al. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome. PLoS One. 2017;12(3):e0172147.
Kelly S, Rodeghier M, DeBaun MR. Automated exchange compared to manual and simple blood transfusion attenuates rise in ferritin level after 1 year of regular blood transfusion therapy in chronically transfused children with sickle cell disease. Transfusion. 2020;60(11):2508–2516.
Ali M, Luxton A, Walker W. Serum ferritin concentration and bone marrow iron stores: a prospective study. Can Med Assoc J. 1978;118(8):945.
Mast AE, Blinder MA, Gronowski AM, Chumley C, Scott MG. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem. 1998;44(1):45–51.
Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013;87(2):98–104.
Vichinsky E, Kleman K, Embury S, Lubin B. The diagnosis of iron deficiency anemia in sickle cell disease. Blood. 1981;58(5):963–968.
Pecker LH, Schaefer BA, Luchtman‐Jones L. Knowledge insufficient: the management of haemoglobin SC disease. Br J Haematol. 2017;176(4):515–526.
Lionnet F, Hammoudi N, Stojanovic KS, Avellino V, Grateau G, Girot R, et al. Hemoglobin sickle cell disease complications: a clinical study of 179 cases. Haematologica. 2012;97(8):1136–1141.
Castro OL, de Franceschi L, Ganz T, Kanter J, Kato GJ, Pasricha SR, et al. Iron restriction in sickle cell disease: when less is more. Am J Hematol. 2024;99:1349–1359.
Sonnweber T, Nairz M, Theurl I, Petzer V, Tymoszuk P, Haschka D, et al. The crucial impact of iron deficiency definition for the course of precapillary pulmonary hypertension. PLoS One. 2018;13(8):e0203396.
Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JSR, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol. 2011;58(3):300–309.
Ruiter G, Lankhorst S, Boonstra A, Postmus P, Zweegman S, Westerhof N, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J. 2011;37(6):1386–1391.
Kalff A, Dowsing C, Grigg A. The impact of a regular erythrocytapheresis programme on the acute and chronic complications of sickle cell disease in adults. Br J Haematol. 2010;149(5):768–774.
Michot JM, Driss F, Guitton C, Moh Klaren J, Lefebvre F, Chamillard X, et al. Immunohematologic tolerance of chronic transfusion exchanges with erythrocytapheresis in sickle cell disease. Transfusion. 2015;55(2):357–363.